| Clinical studies examining hematologic improvement in transfusion dependent lower IPSS risk MDS patients receiving iron chelation therapy. | |||||
|---|---|---|---|---|---|
| Study | N (RBC, NEUTS, PLTS) |
Erythroid response |
Neutrophil response |
Platelet response |
Reference |
| Jensen 19961 | 5 | 5 TI | NR | NR | [1] |
| Cilloni 20112 | 57 | 45.6% | NR | NR | [2] |
| List 2012 |
173 52 77 |
15% | 15% | 22% | [3] |
| Gattermann 2012 |
247 50 100 |
21.5% | 22% | 13% | [4] |
| Nolte 2012 | 50 | 11% | NR | NR | [5] |
| Angelucci 2012 | 152 |
TI in 12% at 12 months |
NR | NR | [6] |
| Breccia 2015 | 40 | 45.6 | NR | NR | [7] |
| Maurillo 20153 | 105 | 7.1 | 7.1 | 5.9 | [8] |
| Rose 2016 | 57 | 19% at 12 months | NR | NR | [9] |
| Messa 20174 | 98 | 45.6 | NR | NR | [10] |
| AA, aplastic anemia; AML, acute myeloid leukemia; DFX, deferasirox; DFO, deferoxamine; N, number; NEUTS, neutrophils; NR, not reported; PLTS, platelets; PMF, primary myelofibrosis; RBC, red blood cell; TI, transfusion independence 1with DFO, all other studies with DFX. 2including 16 PMF, 8 AA and 2 AML. 3including 16 with higher risk MDS. 4including 15 PMF, 8 AA and 2 AML. From: Leitch HA, et al. Leuk Res. 2018;74:21-41. | |||||